Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
GSK has signed a multi-year, multi-target strategic research alliance with biotech start-up Rgenta Therapeutics.
read more
GSK has signed a research alliance with Danish biotech start-up Muna Therapeutics focused on novel drug targets for the treatment of Alzheimer’s.
read more
The generics giant has entered into an agreement with JKI to divest Teva-Takeda, its generics business venture in Japan.
read more
The phase 3 trial win for its D1/D5 partial agonist tees up AbbVie for an NDA submission in 2025.
read more
Lonza has unveiled a new organizational structure that focuses on its core CDMO services, which includes shedding its Capsules & Health Ingredients business.
read more
AbbVie will pick up Nimble’s lead asset, a preclinical oral peptide IL23R inhibitor in development for the treatment of psoriasis.
read more
The FDA has identified cases of serious liver injury among patients being treated for primary biliary cholangitis who did not have cirrhosis of the liver.
read more
Crenessity offers a breakthrough in the treatment landscape for classic CAH.
read more
Per the deal, Terray will utilize its tNova platform to discover and develop small molecule compounds against a set of targets selected by Gilead.
read more
India’s ACG has kicked off operations at its new 1.89 million-square-foot capsule manufacturing facility in Rayong, Thailand.
read more
With three out of four trials hitting primary endpoints, Axsome will submit its dextromethorphan/bupropion combo to the FDA for Alzheimer’s agitation.
read more
Products sold over the counter may contain undeclared tadalafil and sildenafil and could be harmful.
read more
A simple dietary supplement may provide a new approach to boost CAR-T cell function, according to UPenn researchers.
read more
The Denmark-based startup will focus on high-value oral alternatives to blockbuster injectable biologics.
read more
Denali revealed disappointing topline results from a phase 2/3 trial evaluating its eIF2B agonist in the treatment of amyotrophic lateral sclerosis.
read more